secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-08-18T20:06:04+00:00
Accession:  0001104659-26-098335
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Board approved 1-for-50 reverse stock split; effective at close of trading Aug 20, 2026; split-adjusted trading on Nasdaq Capital Market Aug 21, 2026 under LIMN.
- Outstanding shares would drop from 67,160,362 to ~1,343,208 (as of July 2, 2026); fractional shares rounded up; CUSIP changes to 53271X 207.
- Nasdaq Panel granted transfer to Capital Market effective Aug 4, 2026; must show $1.00 closing bid for 10 consecutive days by Sept 3, 2026 to regain compliance.
- Company had been non-compliant with MVLS, MVPHS, and bid price rules; regained compliance with stockholders' equity and MVPHS requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926098335/0001104659-26-098335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926098335/tm2623497d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-098335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer